Key clinical point: Pancreatic ductal adenocarcinoma specimens often harbor mutations that are potentially targetable with currently approved agents.
Major finding: A total of 608 (17%) of specimens harbored mutations that are considered actionable targets. These involved either the receptor tyrosine kinase/ras/mitogen-activated protein kinase signaling or DNA damage repair pathways.
Study details: A targeted genomic profile analyses of 3,594 pancreatic ductal adenocarcinoma tumor specimens from an international cohort.
Disclosures: Funders included the Pancreatic Cancer Action Network, the National Pancreas Foundation, and the Sky Foundation. Dr. Singhi and two coinvestigators reported receiving honoraria from Foundation Medicine, and seven other coinvestigators reported employment by and stock ownership in Foundation Medicine. No other disclosures were reported.
Singhi AD et al. Gastroenterology. 2019 Mar 2. doi: 10.1053/j.gastro.2019.02.03.